Inflammatory Bowel Diseases: World Drug Market 2013-2023

July 2013 | 120 pages | ID: IFB4D015C9EEN
Visiongain

Abstracts

Medicines for bowel inflammation - you explore R&D and potential sales

What's the future for treating inflammatory bowel diseases (IBD)? Visiongain's updated report gives you revenue predictions from 2013, helping you stay ahead. There you find financial results, R&D trends, opportunities, and potential revenues.

In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging technologies. Try our new report.

Analysis of what shapes the IBD drugs industry and determines its potential

Discover what the future holds for agents treating inflammatory bowel disorders: Crohn's disease and ulcerative colitis. Read on, then, to explore that drug industry and see what its future market could be worth.

Forecasts to 2023 and other data show you commercial potentials

Besides revenue forecasting, our new work shows recent results, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments (R&D). You also get 74 tables, 34 charts, and three interviews.

You know how hard it can be to find data. All that searching. Now, though, you can stay ahead in knowledge for IBD medicine, benefiting your research, analyses, and decisions.

Avoid falling behind. Also save time. Finding information you need just got easier. There, in our study, you hear what's happening and see where the money lies.

The following sections, then, show what you get in our new investigation.

Prospects for the world market and submarkets for IBD medications

Our report shows revenue to 2023 for the overall world IBD drug market. It also shows you individual forecasts for five submarkets:

• Aminosalicylates
• Antibiotics
• Corticosteroids
• Biologic therapies (biological drugs)
• Immunomodulators.

How will those colonic medicines perform? Which classes of lower-gut treatment will generate most money? There you assess prospects for revenue growth.

Our study gives you a feel for what stimulates and restrains that industry and market. That analysis helps you identify potential for those intestinal medicines. See how you can benefit.

You also find revenue predictions for leading products.

Forecasts for IBD drugs - what outlooks for sales?

How will top drugs perform to 2023 at world level? Our report forecasts individual revenues of 14 products, including these:

• Humira
• Remicade
• Asacol
• Pentasa
• Lialda
• Tysabri
• Xifaxan
• Cimzia
• Entocort.

There you discover how high sales can go, to 2023, finding products and years with highest predicted growth and revenues. Also you examine competition. You see what's happening, then, understanding trends, competition, challenges, and opportunities.

Our investigation also divides its overall IBD world forecast into geographical regions.

National markets for treating those gastrointestinal disorders

Developments worldwide expand the inflammatory bowel treatment market. Hear about the best revenue prospects.

In developed and developing countries, many opportunities for producers and sellers of those drugs will occur from 2013 to 2023. See where and how.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:

• US
• Japan
• Germany, France, UK, Italy, and Spain (EU5)
• China, India, Brazil, and Russia (BRIC).

There you discover progress and outlooks. Product launches from 2013 to 2023 will change the commercial landscape.

Research and development - assess innovation, trends, and possibilities

What about R&D - pipelines for new drugs? You assess trends there, including for these agents:

• Interleukin (IL) inhibitors
• Cell-adhesion molecule (CAM) inhibitors
• TNF alpha inhibitors
• Stem cell therapies
• Immunomodulators
• Chemokine receptors
• Antioxidants and barrier function therapies.

That R&D explores many molecular pathways and targets. It holds promise. You hear about innovations there - developments and their significance. Discover progress.

For large companies and specialty pharma firms there exist many opportunities. Our new study explains, discussing issues to help your work.

Issues affecting manufacturing and selling of IBD treatments

Our report also shows you issues and events affecting that industry and market from 2013, including these:

• Nature of ulcerative colitis and Crohn's disease
• Aetiology and epidemiology of IBD
• Monoclonal antibodies (mAbs) as medications
• Delivery systems for agents
• Vaccines and alternative therapy
• Genotyping and improvements to treatments.

There you explore political, economic, social, and technological questions, assessing outlooks for the business. You also analyse that industry's strengths, weaknesses, opportunities, and threats. Discover now what the future holds.

Companies leading that industry and 2017 market value

From 2013, new treatments hold great potential for investment, technological advances and high revenues. Our study predicts the world market for IBD drugs will reach $9.6bn in 2017, and expand further to 2023.

Our work shows you what technologies, products, and organisations hold greatest potential. In particular, it investigates these companies:

• AbbVie
• Janssen Biotech
• Warner Chilcott
• Shire Pharmaceuticals.

From 2013 there exist prospects for new drugs and overall sales growth. Our report shows you the possibilities, helping you stay ahead.

Eight ways Inflammatory Bowel Diseases: World Drug Market 2013-2023 helps you

To sum up, then, our research and analysis give you the following knowledge:

• Revenue to 2023 of the world market for IBD medicines - discover that industry's overall sales potential
• Revenues to 2023 for 5 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and sales
• Revenues to 2023 for 14 products - find sales outlooks for top brands, seeing how they can compete and succeed
• Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth
• Assessments of top companies - hear about participants' activities, capabilities, results, and outlooks
• Review of R&D - explore progress in research and development, finding technological and medical possibilities
• Interviews with authorities on the field - discover debates and opinions to help you stay ahead
• Competition and opportunities - investigate what shapes that market's future, including ways to develop business and succeed.

Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our new report, discovering where prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity for treating those gastrointestinal diseases. See there how you could benefit your research, analyses, and decisions. Also find how you can save time and get recognition for commercial insight.

Treatment of IBD - assess its potential now, seeing what you can gain

Our new study shows you data, trends, opportunities, and sales predictions for drugs treating inflammatory bowel disorders. Avoid missing out - please order our report now.

Contents

1. EXECUTIVE SUMMARY

1.1 Inflammatory Bowel Disease Market Overview
1.2 Aims, Scope and Format of the Report
1.3 Chapter Outlines
1.4 Research and Analysis Methods

2. INTRODUCTION TO THE INFLAMMATORY BOWEL DISEASE MARKET

2.1 What is Inflammatory Bowel Disease (IBD)?
2.2 Are There Different Types of IBD?
2.3 Signs, Symptoms and Associated Conditions
2.4 What Causes Inflammatory Bowel Disease?
2.5 How Common is Inflammatory Bowel Disease?

3. DRUG TREATMENTS FOR INFLAMMATORY BOWEL DISEASES

3.1 Can IBD be Cured?
3.2 What Are the Medications Used to Treat IBD?
  3.2.1 Aminosalicylates - The Most Common Therapy
  3.2.2 Corticosteroids - Limited in the Long-Run?
  3.2.3 Immunomodulators - Slow to Act?
  3.2.4 Monoclonal Antibodies - The Future?
  3.2.5 Antibiotics - Do they Really Help?
3.3 Treatment Protocol

4. THE WORLD INFLAMMATORY BOWEL DISEASE MARKET, 2013-2023

4.1 The Inflammatory Bowel Disease Market in 2012: Domination of Biologics and Aminosalicylates
4.2 Forecast 2013-2023: Any Major Changes Expected?
4.3 Aminosalicylates Forecast 2013-2023: The Work-Horse of IBD Therapy
4.4 Antibiotics Forecast 2013-2023: Will They Still Be Relevant in a Decade?
4.5 Biologic Therapies Forecast 2013-2023: Main Driver of Growth
4.6 Corticosteroids Forecast 2013-2023: Continued Insignificance?
4.7 Immunomodulators Forecast 2013-2023

5. LEADING NATIONAL MARKETS, 2013-2023

5.1 IBD Drugs - Leading National Markets, 2012
5.2 The US IBD Drug Market, Revenues 2013-2023 - Leader of the Pack
  5.2.1 Case Study: What is the Relative Contribution of Ulcerative Colitis and Crohn's Disease to Total IBD Spending in the US?
5.3 The Japanese IBD Drug Market, Revenues 2013-2023 - Tomorrow's Leader?
5.4 The EU-5 IBD Drug Markets, Revenues 2013-2023 - Europe's Growth Potential
5.5 IBD Drug Markets in BRIC Countries, Revenues 2013-2023 - Vast Potential for Sales
  5.5.1 Brazil: Revenues 2013-2023
  5.5.2 Russia: Revenues 2013-2023
  5.5.3 India: Revenues 2013-2023
  5.5.4 China: Revenues 2013-2023

6. MARKET PROSPECTS FOR LEADING IBD DRUGS, 2013-2023

6.1 Humira (AbbVie) - The Leading Therapy
  6.1.1Humira: Forecast and Analysis, 2013-2023
6.2 Remicade (Janssen Biotech) - A Worthy Challenger?
  6.2.1Remicade: Forecast and Analysis, 2013-2023
6.3 Asacol (Warner Chilcott) - The Best Mesalazine Formulation?
  6.3.1Asacol: Forecast and Analysis, 2013-2023
6.4 Pentasa (Shire USA) - When Will a Generic Substitute Arrive?
  6.4.1 Pentasa: Forecast and Analysis, 2013-2023
6.5 Lialda (Shire USA) - What Potential for that Medication?
  6.5.1 Lialda: Forecast and Analysis, 2013-2023
6.6 Tysabri (Elan Pharmaceuticals) - Will Side Effects Prove Too Much?
  6.6.1 Tysabri: Forecast and Analysis, 2013-2023
6.7 Xifaxan (Salix Pharmaceuticals)
  6.7.1 Xifaxan: Forecast and Analysis, 2013-2023
6.8 Cimzia (UCB Inc.) - Approved in Only a Handful of Countries
  6.8.1 Cimzia: Forecast and Analysis, 2013-2023
6.9 Entocort (AstraZeneca) - Prominent Steroid Treatment
  6.9.1 Entocort: Forecast and Analysis, 2013-2023
6.10 Neoral (Novartis) - A Widely Used Immunosuppressant
  6.10.1 Neoral: Forecast and Analysis, 2013-2023
6.11 Medrol (Pfizer Inc.) - Another Leading Steroid
  6.11.1 Medrol: Forecast and Analysis, 2013-2023
6.12 Canasa/Salofalk (Aptalis Pharmaceuticals) - A Slow Decline
  6.12.1 Canasa/Salofalk: Forecast and Analysis, 2013-2023
6.13 Apriso (Salix Pharmaceuticals) - A Serious Challenger to Asacol?
  6.13.1 Apriso: Forecast and Analysis, 2013-2023
6.14 Azulfidine (Pfizer Inc.) - What Scope for Revenue Growth?
  6.14.1 Azulfidine: Forecast and Analysis, 2013-2023

7. THE R&D PIPELINE FOR INFLAMMATORY BOWEL DISEASE, 2013

7.1 Interleukin (IL) Inhibitors - One of the Main Areas of Innovation
  7.1.1 Profile: Vidofludimus (4SC)
7.2 Cell-Adhesion Molecule (CAM) Inhibitors - A Promising Avenue
  7.2.1 Profile: Etrolizumab (Roche)
7.3 TNF-? Inhibitors - A Tried and Tested Target
  7.3.1 Profile: Ozoralizumab (Ablynx)
7.4 Stem Cell Therapies - Basis for a Cure?
  7.4.1 Profile: Remestemcel-L (Osiris Therapeutics)
7.5 Janus Kinase (JAK) Inhibitors - More Targets to Hit
  7.5.1 Profile: Tasocitinib (Pfizer)
7.6 Immunomodulators - Will They Live Up To the Hype?
  7.6.1 Profile: ZP1848 (Zealand Pharma)
7.7 Chemokine Receptors - Potential Exists
  7.7.1 Profile: Vercirnon (ChemoCentryx/GSK)
7.8 Antioxidants and Barrier Function
  7.8.1 Profile: Tetomilast (Otsuka) - The Future of IBD Treatment?

8. DRIVERS AND RESTRAINTS IN THE INFLAMMATORY BOWEL DISEASE DRUG INDUSTRY AND MARKET, 2013-2023

8.1 SWOT and STEP Analysis of the IBD Market
8.2 What Factors Will Drive the IBD Market?
  8.2.1 Increasing Disease Incidence
  8.2.2 Better Diagnosis
  8.2.3 Nature of the Disease
  8.2.4 Delivery Systems
  8.2.5 Biological Drugs
  8.2.6 Socioeconomic Costs of IBD
8.3 What Factors Will Restrain the Market?
  8.3.1 Lack of Understanding of Disease Aetiology
  8.3.2 Compliance
  8.3.3 Limits of Biologics
  8.3.4 A Cure or Vaccine
  8.3.5 The Possible Development of Alternative Treatments
  8.3.6 Surgery - When Other Options Fail

9. LEADING COMPANIES IN THE IBD MARKET, 2013

9.1 The Largest Companies by Revenue
9.2 AbbVie - The Leader in a Highly Profitable Area
9.3 Janssen Biotech - Tomorrow's Powerhouse?
9.4 Warner Chilcott - A Strong Competitor
9.5 Shire Pharmaceuticals - Still a Major Player in the Future?

10. RESEARCH INTERVIEWS

10.1 Dr Qamar ul Arfin, Gastroenterologist, Aga Khan University Hospital, Karachi, Pakistan
  10.1.1 On Antibiotics in Treating IBD
  10.1.2 On the Emergence of Biologic Therapies
  10.1.3 On IBD in the Pakistani Context
  10.1.4 On Any Preventative Measures that Can Be Taken
10.2 Professor John Hermon-Taylor, King's College London
  10.2.1 The Significance of MAP in Crohn's
  10.2.2 Rising Incidence of IBD
  10.2.3 Defining IBD
  10.2.4 Timeframe of MAP Vaccine
  10.2.5 Antibiotic Activity of Other Crohn's Treatments
  10.2.6 Alternative Treatments
  10.2.7 Ethics of Crohn's Drug Development
  10.2.8 The Impact of a Vaccine on the Market
  10.2.9 On Claims that MAP is Not Implicated in CD
10.3 Professor Thomas Barody, Director, Centre for Digestive Diseases, Sydney
  10.3.1 Mycobacterium Avium Paratuberculosis (MAP) Infection and IBD Aetiology
  10.3.2 IBD and HIV/AIDS
  10.3.3 Monoclonal Antibodies and Immunosuppressant Treatments
  10.3.4 Potential Cure?
  10.3.5 Remicade and MAP
  10.3.6 Genotyping
  10.3.7 Crohn's vs. Colitis
  10.3.8 Future Therapies
  10.3.9 The Potential and Future of Myoconda

11. CONCLUSIONS

11.1 IBD Market to Expand from 2013 to 2023
11.2 Aminosalicylates and Other Non-Biologic Treatments
11.3 Biologic Treatments
11.4 Improvements Needed in IBD Treatments
11.5 Future IBD Treatments: R&D Efforts Look Promising
11.6 The IBD Sector: Looking to the Future with Confidence

List Of Tables

LIST OF TABLES

Table 2.1 World Incidence Rates for IBD, 2013
Table 2.2 Geographical Variations in the Incidence of IBD, 2013
Table 3.1 Other Drug Types Used to Treat IBD, 2013
Table 4.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2011 and 2012
Table 4.2 Global IBD Drug Market Forecast ($m), 2012-2023
Table 4.3 Global IBD Drug Forecast by Drug Category ($m), 2012-2023
Table 4.4 Global IBD Drug Market Drivers and Restraints, 2012-2023
Table 4.5 Global Aminosalicylates Forecast ($m), 2012-2023
Table 4.6 Global Aminosalicylates Drivers and Restraints, 2012-2023
Table 4.7 Global Antibiotics Forecast ($m), 2012-2023
Table 4.8 Global Antibiotics Drivers and Restraints, 2012-2023
Table 4.9 Global Biologic Therapies Forecast ($m), 2012-2023
Table 4.10 Global Biologic Therapies Drivers and Restraints, 2012-2023
Table 4.11 Global Corticosteroid Forecast ($m), 2012-2023
Table 4.12 Global Corticosteroids Drivers and Restraints, 2012-2023
Table 4.13 Global Immunomodulators Forecast ($m), 2012-2023
Table 4.14 Global Immunomodulators Drivers and Restraints, 2012-2023
Table 5.1 Global IBD Drug Revenues by Geographical Segments ($m), 2012
Table 5.2 Global IBD Drug Market Forecasts by Country ($m), 2012-2023
Table 5.3 US IBD Drug Market Forecast ($m), 2012-2023
Table 5.4 Japanese IBD Drug Market Forecast ($m), 2012-2023
Table 5.5 EU5 IBD Drug Market Forecasts ($m), 2012-2023
Table 5.6 BRIC IBD Drug Market Forecasts ($m), 2012-2023
Table 5.7 Brazilian IBD Drug Market Forecast ($m), 2012-2023
Table 5.8 Russian IBD Drug Market Forecast ($m), 2012-2023
Table 5.9 Indian IBD Drug Market Forecast ($m), 2012-2023
Table 5.10 Chinese IBD Drug Market Forecast ($m), 2012-2023
Table 6.1 Leading IBD Treatments by Revenue ($m), 2012
Table 6.2 Leading IBD Medicines: Revenue Forecasts ($m), 2012-2023
Table 6.3 World Humira Revenue Forecast ($m), 2012-2023
Table 6.4 Drivers and Restraints for Humira, 2012-2023
Table 6.5 World Remicade Revenue Forecast ($m), 2012-2023
Table 6.6 Drivers and Restraints for Remicade, 2012-2023
Table 6.7 World Asacol Revenue Forecast ($m), 2012-2023
Table 6.8 Drivers and Restraints for Asacol, 2012-2023
Table 6.9 World Pentasa Revenue Forecast ($m), 2012-2023
Table 6.10 Drivers and Restraints for Pentasa, 2012-2023
Table 6.11 World Lialda Revenue Forecast ($m), 2012-2023
Table 6.12 Drivers and Restraints for Lialda, 2012-2023
Table 6.13 World Tysabri Revenue Forecast ($m), 2012-2023
Table 6.14 Drivers and Restraints for Tysabri, 2012-2023
Table 6.15 World Xifaxan Revenue Forecast ($m), 2012-2023
Table 6.16 Drivers and Restraints for Xifaxan, 2012-2023
Table 6.17 World Cimzia Revenue Forecast ($m), 2012-2023
Table 6.18 Drivers and Restraints for Cimzia, 2012-2023
Table 6.19 World Entocort Revenue Forecast ($m), 2012-2023
Table 6.20 Drivers and Restraints for Entocort, 2012-2023
Table 6.21 World Neoral Revenue Forecast ($m), 2012-2023
Table 6.22 Drivers and Restraints for Neoral, 2012-2023
Table 6.23 World Medrol Revenue Forecast ($m), 2012-2023
Table 6.24 Drivers and Restraints for Medrol, 2012-2023
Table 6.25 World Canasa Revenue Forecast ($m), 2012-2023
Table 6.26 Drivers and Restraints for Canasa, 2012-2023
Table 6.27 World Apriso Revenue Forecast ($m), 2012-2023
Table 6.28 Drivers and Restraints for Apriso, 2012-2023
Table 6.29 World Azulfidine Revenue Forecast ($m), 2012-2023
Table 6.30 Drivers and Restraints for Azulfidine, 2012-2023
Table 7.1 Selected IL Inhibitors in Clinical Development, 2013
Table 7.2 Selected CAM Inhibitors in Clinical Development, 2013
Table 7.3 Selected TNF-Alfa Inhibitors in Clinical Development, 2013
Table 7.4 Selected Stem Cell Therapies in Clinical Development, 2013
Table 7.5 Selected Immunomodulators in Clinical Development, 2013
Table 7.6 Selected Chemokine Receptors in Clinical Development, 2013
Table 7.7 Selected Antioxidants and Barrier Function Therapies in Clinical Development, 2013
Table 8.1 SWOT Analysis of the World IBD Drug Market, 2012-2023
Table 8.2 STEP Analysis of the World IBD Drug Market, 2012-2023
Table 9.1 Top 4 Companies for IBD Drugs: Revenues ($m) and Market Shares (%), 2012
Table 9.2 AbbVie Revenues ($m) and Market Share (%), 2012
Table 9.3 Janssen Biotech Revenues ($m) and Market Share (%), 2012
Table 9.4 Warner Chilcott Revenues ($m) and Market Share (%), 2012
Table 9.5 Shire's Revenues ($m) and Market Share (%), 2012
Table 11.1 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Product Category, 2013, 2017, 2023
Table 11.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Geographical Regions, 2013, 2017, 2023
Table 11.3 Summary of IBD Market Drivers and Restraints, 2013-2023

About

Lialda (Shire USA) – What Potential for that Medication?

Lialda is a new formulation of mesalazine, and is used to treat inflammation in the colon. Like Asacol, Lialda consists of a pH dependent coating surrounding a core of mesalazine. Lialda's main selling point is that it is a once-daily formulation, in contrast to most other 5-ASA drugs, which require several doses throughout the day.

The FDA approved Lialda in the US in 2007. It was released in the UK, as Mezavant, in the same year, and is now available in most of Europe under this name.

Lialda: Forecast and Analysis, 2013-2023

Lialda has achieved impressive growth since its release in 2007. In 2012, it generated revenues of $400m worldwide, which represents a 7.53% increase over the 2011 revenue figure 0f $372m. Visiongain expects this growth to continue, but at a significantly reduced level. By 2017 Lialda will generate sales of $869m, but by 2023 its revenues will have fallen to $750.9m. The CAGR over the forecast period was calculated to be 5.23%. Since Lialda’s patent expires in 2020, visiongain expects it to come under generic competition after this date, and this will cause revenues to begin contracting.

Lialda has similar efficacy to Asacol but is more convenient to use because of its once daily dosing. In 2009, Shire presented the results of a 12-month persistency analysis of mesalazine therapies. Lialda patients were twice as likely to refill their prescription within a set period as patients on other mesalazine-based drugs, suggesting increased compliance and satisfaction with the therapy.

Lialda acts on colon, just as Asacol does. However, since it is more convenient to use, it may replace Asacol as the gold standard treatment for UC. Visiongain predicts that Lialda will erode Asacol's market share during the forecast period. However, it is worth noting that doctors are unlikely to switch patients to Lialda from other 5-ASAs that are still generating results for their patients, and for this reason, Lialda’s growth will be somewhat slower than otherwise expected.